Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ...United Arab Emirates

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' )

Also on site :

• What’s Next for Iran After the U.S.-Israel Strike on Its Nuclear Sites?
• Huawei Digital Power accueille le forum Grid Forming & ESS Safety pour des stratégies commerciales innovantes et un écosystème de sécurité
• How Yemeni Cafes like Haraz Coffee House Are Building Momentum and Community